An open study of interferon in HIV-antibody-positive men

Alpha-2a-recombinant interferon (Roferon A) was given subcutaneously in a dose of 3 mega units twice weekly for 15-18 months to 14 HIV-antibody-positive, p24-antigen-negative men with minimal HIV-related disease. Interferon was well-tolerated and safe. Although there was either improvement or lack o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	AIDS (London) 1989-12, Vol.3 (12), p.851-853
Hauptverfasser:	Ellis, M E, Haeney, M R, Craske, J, Potter, M R, Turner, A J, Shipman, J, Blackburn, N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult AIDS/HIV CD4-Positive T-Lymphocytes Gene Products, gag - analysis HIV Antigens - analysis HIV Core Protein p24 HIV Infections - therapy HIV Seropositivity Humans Injections, Subcutaneous Interferon alpha-2 Interferon Type I - therapeutic use Interferon-alpha - administration & dosage Interferon-alpha - therapeutic use Leukocyte Count Lymphocytes Male Middle Aged Recombinant Proteins Self Administration T-Lymphocytes, Regulatory Viral Core Proteins - analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Alpha-2a-recombinant interferon (Roferon A) was given subcutaneously in a dose of 3 mega units twice weekly for 15-18 months to 14 HIV-antibody-positive, p24-antigen-negative men with minimal HIV-related disease. Interferon was well-tolerated and safe. Although there was either improvement or lack of deterioration initially in 22 out of 26 HIV disease markers, including lymphadenopathy, thrombocytopenic purpura and nail fungal infection, there were 11 instances of HIV disease indicators appearing during the study. At 15 months, six patients were withdrawn from the study because of clinical and immunological deterioration.
ISSN:	0269-9370
DOI:	10.1097/00002030-198912000-00012